RetinalGeniX Technologies Inc. Focuses on Prevention of Blindness and Early Detection of Multiple Systemic Diseases
September 18, 2023 05:59 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) released to the public via OTC Markets, a video webinar regarding...
Neuromeka Participates in FABTECH 2023, Unveiling 3D Vision Collaborative Robot Welding Solution
September 13, 2023 18:45 ET
|
Neuromeka USA, Inc.
CHICAGO, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Neuromeka unveiled its collaborative robot welding solution during FABTECH 2023, North America's largest metal forming, fabricating, welding and finishing...
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
August 28, 2023 07:00 ET
|
ONL Therapeutics
More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 Ophthalmic Solution as adjunct to standard-of-care surgery Topline data readout...
RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS
August 28, 2023 06:35 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced the addition of Fred Chasalow, Ph.D., to the...
RetinalGeniX Technologies Inc. Granted Patent for Patient Home Monitoring and Physician Alert System for Ocular Anatomy
July 28, 2023 13:24 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), this week was granted a patent for its Patient Home Monitoring...
Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression
July 11, 2023 09:00 ET
|
Nacuity Pharmaceuticals, Inc.
New clinical site added and early safety signals observed in trial for treatment of ocular disease caused by oxidative stress First cohort is expected to achieve full enrollment by third quarter...
RetinalGeniX Technologies, Inc. Nears Completion of Institutional Review Board for Research on DNA/GPS Program
June 26, 2023 06:15 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today previewed the completion of an Institutional Review Board...
Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPS
June 07, 2023 05:35 ET
|
RetinalGeniX Technologies, Inc.
PETALUMA, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), announced today the hiring of Owen Watson, MS. Mr. Watson’s...
The Automated Guided Vehicles Market is projected to grow from USD 2.17 billion in 2022 to USD 4.11 billion by 2030, exhibiting a CAGR of 9.6% during the forecast period.| Data By Contrive Datum Insights Pvt Ltd.
May 11, 2023 17:00 ET
|
Contrive Datum Insights Pvt Ltd
Farmington, May 11, 2023 (GLOBE NEWSWIRE) -- The Global Automated Guided Vehicles Market is projected to grow from USD 2.17 billion in 2022 to USD 4.11 billion by 2030, exhibiting a CAGR of 9.6%...
Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa
May 04, 2023 03:00 ET
|
Endogena
SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, May 04, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed...